Zenas BioPharma, Inc. (ZBIO)
| Market Cap | 1.66B +48.1% |
| Revenue (ttm) | 1,000,000 -93.3% |
| Net Income | -484.38M |
| EPS | -9.05 |
| Shares Out | 65.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 471,886 |
| Open | 24.96 |
| Previous Close | 24.86 |
| Day's Range | 24.25 - 25.94 |
| 52-Week Range | 13.50 - 44.60 |
| Beta | -0.88 |
| Analysts | Strong Buy |
| Price Target | 47.88 (+88.5%) |
| Est. Earnings | Nov 11, 2026 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an ext... [Read more]
Financial Performance
In 2025, Zenas BioPharma's revenue was $10.00 million, an increase of 100.00% compared to the previous year's $5.00 million. Losses were -$377.74 million, 140.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price target is $47.88, which is an increase of 88.50% from the latest price.
News
Zenas BioPharma presents new obexelimab data
Zenas BioPharma (ZBIO) announced new obexelimab data in immunoglobulin G4-related disease, or IgG4-RD, presented at the 6th International Symposium on IgG4-Related Disease, held October 8-10 in Cambri...
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients li...
Zenas BioPharma to Host Virtual R&D Event
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma price target raised to $48 from $41 at Citi
Citi raised the firm’s price target on Zenas BioPharma (ZBIO) to $48 from $41 and keeps a Buy rating on the shares after updating the firm’s obexelimab forecasts to account…
Zenas BioPharma Transcript: Study update
In phase III INDIGO, 73.2% of obexelimab-treated patients remained flare-free through week 52 (HR 0.443); all key secondary endpoints were met, with lower glucocorticoid toxicity worsening. Launch plans target a U.S. opportunity approaching $4 billion.
Zenas BioPharma Slides: Study update
Zenas BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Zenas BioPharma announces new data from Phase 3 INDIGO trial on obexelimab
Zenas BioPharma (ZBIO) announced that new data from the Phase 3 INDIGO trial evaluating obexelimab in immunoglobulin G4-related disease will be presented at two upcoming scientific meetings: the 6th I...
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas BioPharma Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Multiple late-stage and early pipeline programs are advancing, with obexelimab nearing potential FDA approval for IgG4-RD and key data readouts expected in lupus and MS. The company is preparing for commercial launch, regulatory submissions in the U.S. and Europe, and sees strong potential for its novel B-cell inhibition approach.
Zenas BioPharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Significant financial strength supports a robust pipeline, with obexelimab poised for potential FDA approval and launch in IgG4-RD. Market research indicates strong front-line adoption, and multiple late- and early-stage programs are advancing, with key data readouts expected by year-end.
Zenas BioPharma files to sell 7.0M shares of common stock for holders
16:50 EDT Zenas BioPharma (ZBIO) files to sell 7.0M shares of common stock for holders
Zenas BioPharma Transcript: Citigroup’s Biopharma Back to School Summit 2026
Multiple late-stage programs are advancing, with obexelimab under FDA review and key data readouts expected in the coming quarters. Market research suggests strong commercial potential in IgG4-RD, and the company is expanding its pipeline in autoimmune and neuroimmunology indications.
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas BioPharma Slides: Corporate presentation
Zenas BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas BioPharma price target raised to $32 from $22 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Zenas BioPharma (ZBIO) to $32 from $22 and keeps an Equal Weight rating on the shares.
Zenas BioPharma reports Q2 EPS ($1.77), consensus (75c)
Reports Q2 revenue $1M, consensus $15M. “2026 continues to be a transformative year for Zenas, highlighted by FDA acceptance of the obexelimab BLA for the treatment of IgG4-RD, with a…
Zenas BioPharma CFO Jennifer Fox to transition out of role
The company announced that Jennifer Fox will transition from her current role as CFO and chief business officer to serve in a new role as strategic advisor to the board…
Zenas BioPharma price target raised to $32 from $22 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Zenas BioPharma (ZBIO) to $32 from $22 and keeps an Equal Weight rating on the shares after the company reported Q2 results…
Zenas BioPharma Slides: Corporate presentation
Zenas BioPharma has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab single-dose prefilled autoinj...
Zenas BioPharma Earnings release: Q2 2026
Zenas BioPharma released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Zenas BioPharma Quarterly report: Q2 2026
Zenas BioPharma has published its Q2 2026 quarterly earnings report on August 13, 2026.
Zenas BioPharma Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
The summit showcased a strong pipeline with obexelimab nearing commercialization for IgG4-RD, supported by positive phase III data and strong market interest. Orelabrutinib and other neuro candidates are advancing in late-stage trials, with several key data readouts and regulatory milestones expected in the next year.